ACC-NK (Antibody-Cell Conjugated NK) is an innovative immune cell therapy targeting solid tumors and hematological malignancies. With non-viral vector and non-gene editing technology, it provides highly effective targeted tumor killing via 5T4, Trop-2, CD33-CLL1 dual-targeting, and synergistic combination therapy with ADC, radiotherapy and chemotherapy.